随着靶向治疗的发展，治疗NSCLC中脑转移的概念正逐渐发生变化。在本文中，我们公布了一名肝细胞生长因子受体（MET）基因扩增和驱动蛋白轻链1-间变性淋巴瘤激酶（KLC1-ALK）融合NSCLC病例，患者表现出对克唑替尼的敏感性，但对化疗没有反应，没有接受放疗。克唑替尼治疗有效控制了脑转移。迄今为止，尚未报道此类携带KL...
间变性淋巴瘤激酶(ALK)重排导致对第二代和第三代 ALK 抑制剂的敏感性,这些疗法已成为 ALK 阳性非小细胞肺癌(NSCLC)的标准治疗。然而,对这些抑制剂的原发性耐药较为罕见,相关了解较少,尤其是驱动蛋白轻链 1(KLC1)/ALK 重排转移性 NSCLC。本文报道了一例ALK阳性伴胸膜转移的NSCLC患者,携带KLC1/ALK基因融合,对...
However, primary resistance to these inhibitors remains a rare and poorly understood phenomenon, especially in cases involving kinesin light chain 1 (KLC1)/ALK-rearranged metastatic NSCLC. Case Description In this report, we present a unique and challenging case of primary resistance to second- and...
最常见的ALK突变类型是 A、EML4-ALK B、KIF5B-ALK C、TFG-ALK D、KLC1-ALK 点击查看答案 手机看题 你可能感兴趣的试题 单项选择题 如何用英语询问客人牛排要几分熟呢? A、What would you like to go with your steak? B、What starter would you like? C、How would you like your steak? D、Would...
Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: A case report. Cancer Biol. Med. 2017, 14, 183-186. [CrossRef]Wang, P.; Xiao, P.; Ye, Y.N.; Liu, P.P.; Han, L.; Dong, L.; ...
A Case of Primary Pulmonary Combined Small Cell Carcinoma With Adenocarcinoma Harboring the Same KLC1-ALK Fusion in Both Histologic Components - ScienceDirectdoi:10.1016/j.jtho.2018.05.018Qianming BaiYuan LiXin ZhangXiaoli ZhuXiaoyan Zhou MD, PhD...
本文报道了一例罕见病例,KLC1/ALK重排肺腺癌胸膜转移患者对第二代和第三代ALK抑制剂原发耐药。 病例 2022年9月,一名34岁男性,从不吸烟,有继发性免疫球蛋白缺陷病病史,进行肺活检,诊断为ALK阳性肺腺癌伴左侧胸膜转移(图1)。NGS检测显示KLC1/ALK重排。2022年10月,开始阿来替尼一线治疗。6周后,呼吸困难加重。胸...